Solana Company Class A Common Stock (DE)
HSDTHelius Medical Technologies, Inc. is a neurotech company focused on developing and commercializing non-invasive neuromodulation therapies to improve brain function and recovery. Their flagship product, the Portable Neuromodulation Stimulator (PoNS), aims to enhance neuroplasticity and aid in rehabilitation for patients with neurological conditions such as traumatic brain injury and stroke. The company emphasizes innovative solutions to address unmet needs in neurological healthcare.
Company News
Forward Industries, Inc. (NASDAQ: FWDI) has made a non-binding proposal to acquire Solana Company. As of July 1, 2026, Forward had 73.8 million outstanding common shares, along with options, RSUs, and warrants for additional shares. The announcement includes disclosure requirements under Irish Takeover Rules.
Forward Industries (NASDAQ: FWDI) announced a non-binding all-stock acquisition proposal to Solana Company (HSDT) on June 15, 2026, offering 0.386 FWDI shares per HSDT share (approximately 10% premium). HSDT's board declined the offer on June 12th without discussion. Forward believes a combined entity would better serve shareholders and the Solan...
Helius Medical Technologies filed a 510(k) submission to the FDA seeking expanded indication for its PoNS device to treat gait and balance deficits in chronic stroke patients, based on clinical trials demonstrating statistically significant improvements in functional gait assessment.
Helius Medical Technologies, Inc. announced the pricing of its public offering of 2,768,600 shares of Class A common stock and warrants to purchase up to 2,768,600 shares of common stock at a combined public offering price of $3.27 per share and accompanying warrants. The offering is expected to raise gross proceeds of $9.1 million.
Helius Medical Technologies has exceeded its initial enrollment target for its stroke registrational program, with 128 participants enrolled as of December 31, 2024. The company expects to reach the maximum enrollment of 150 participants by the end of January 2025 and is on track to submit for FDA authorization for the PoNS device in the stroke i...
